Vyome Holdings inks agreement with Impetis Biosciences to in-license two selective JAK inhibitor assets

image credit- freepik

Vyome Holdings, Inc. has announced the signing of an agreement with Mumbai-based Impetis Biosciences, a TATA Enterprise, that gives it exclusive license to develop and commercialise a selective JAK 1/3 inhibitor and a selective JAK1 inhibitor.

Janus kinase (JAK) inhibitors are immunomodulatory drugs that treat autoimmune and inflammatory conditions by blocking JAK enzymes. Several JAK inhibitors are US FDA-approved to treat a wide range of disease conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, alopecia areata (baldness), atopic dermatitis (eczema), etc.

However, the FDA has previously issued warnings that certain of these older-generation JAK inhibitors are associated with risks, as they are not selective. Selective JAK inhibitors are designed to overcome these risks. The JAK inhibitors market size has grown rapidly in recent years, and is expected to grow from $23.56 billion in 2025 to $56.78 billion by 2030 at a compound annual growth rate (CAGR) of 19.5%.

“We are building Vyome with focus and discipline in one of the most attractive segments in biotech, the immuno-inflammatory market, expected to exceed $430 billion by 2034, with the JAK inhibitor segment alone representing a significant ~$57 billion opportunity,” said Venkat Nelabhotla, CEO of Vyome. “This transaction highlights the strength of the US–India innovation corridor in sourcing high-quality assets efficiently. The transaction is structured to be very capital-efficient, with consideration tied to commercialization. Any future development will be driven through non-dilutive pathways, allowing us to remain fully focused on executing our core strategy around VT-1953.”